These tumor cell-centric ISG responses to activated CPA were at least in part dependent on signaling by the type I IFN receptor, IFNAR1, implicating tumor cell production of type I IFNs in these drug-induced ISG responses. Here, IFNAR1 is linked to neoplasm.